Treatment for SUI may soon be easier to swallow

Chicago-A mixed serotonin and noradrenaline reuptake inhibitor appears to reduce the symptoms associated with stress urinary incontinence (SUI) and improve the quality of life in patients receiving it, according to findings from a phase II clinical trial presented at the American Urogynecologic Society 22nd annual scientific meeting here. While the agent, duloxetine, is still investigational, observers say the prospects for a pharmacologic approach to stress incontinence are promising.